ArticleScientific reports2020
Targeting continuity of care and polypharmacy to reduce drug-drug interaction.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- The Relationship of Continuity of Care, Polypharmacy and Medication Appropriateness: A Systematic Review of Observational Studies.Drugs & aging · 2023Pooled it
- EVALUATION OF SCREENING TOOL OF OLDER PEOPLE'S PRESCRIPTIONS (STOPP) CRITERIA IN AN URBAN COHORT OF OLDER PEOPLE WITH HIV.Pharmacoepidemiology · 2025Article
- Reasons for non-acceptance of statin therapy by patients at high cardiovascular risk.Scientific reports · 2025Article
- Conditions for and potential solutions associated with continuity of care for patients with complex care needs across Swedish regions with differing population densities.BMC health services research · 2025Article
- Prevalence and differences in the co-administration of drugs known to interact: an analysis of three distinct and large populations.BMC medicine · 2024Article
- Deprescribing medications among patients with multiple prescribers: A socioecological model.Journal of the American Geriatrics Society · 2024Article
- Categorical Analysis of Database Consistency in Reporting Drug-Drug Interactions for Cardiovascular Diseases.Pharmaceutics · 2024Article
- Continuity of care and mortality for patients with chronic disease: an observational study using Norwegian registry data.Family practice · 2023Observational
- Measurement of polydoctoring as a crucial component of fragmentation of care among patients with multimorbidity: Cross-sectional study in Japan.Journal of general and family medicine · 2023Article
- Geriatrician-led multidisciplinary team management improving polypharmacy among older inpatients in China.Frontiers in pharmacology · 2023Article
- Association of potentially inappropriate medications and need for long-term care among older adults: a matched cohort study.BMC geriatrics · 2022Article
- Continuity of care for older adults in a Canadian long-term care setting: a qualitative study.BMC health services research · 2022Article
- The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications.Frontiers in pharmacology · 2022Review
- Patient- and Prescriber-Related Factors Associated with Potentially Inappropriate Medications and Drug-Drug Interactions in Older Adults.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-drug interaction (DDI) is common among the elderly, and it can have detrimental effects on patients. However, how DDI can be targeted has been under-researched. This study investigates whether DDI can be reduced by targeting continuity of care (COC) through reducing polypharmacy. Population claims data of Taiwan National Health Insurance were used to conduct a 7-year-long longitudinal study on patients aged ≥ 65 years (n = 2,318,766). Mediation analysis with counterfactual method and a 4-way decomposition of the effect of COC on DDI was conducted. Mediation effect through excessive polypharmacy differed from that through lower-level polypharmacy. Compared with the low COC group, the high COC group demonstrated reduced excess relative risk of DDI by 26% (excess relative risk = - 0.263; 95% Confidence Interval (CI) = - 0.263 to - 0.259) to 30% (excess relative risk = - 0.297; 95% CI = - 0.300 to - 0.295) with excessive polypharmacy as the mediator. The risk only reduced by 8% (excess relative risk = - 0.079; 95% CI, - 0.08 to - 0.078) to 10% (excess relative risk = - 0.096; 95% CI, - 0.097 to - 0.095) when the mediator was changed to lower-level polypharmacy. The effect of COC on DDI was mediated by polypharmacy, and the mediation effect was higher with excessive polypharmacy. Therefore, to reduce DDI in the elderly population, different policy interventions should be designed by considering polypharmacy levels to maximize the positive effect of COC on DDI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.